Because of the serious nature of penicillin-resistant staphylococcal infections, there is a continuing need for effective antibacterial agents. Ristocetin (Spontin*), one of the newer antibiotics, is bactericidal and effective against staphylococci as well as other Gram-positive organisms.1-3The purpose of this study was to review our clinical experiences with this antibiotic in regard to clinical effectiveness, method of administration, and toxicity. Material and Method Seventy-six hospitalized patients were treated with ristocetin for various types of pyogenic infections. Twenty-seven of these were severely ill and received other antibiotics in addition to ristocetin. Forty-seven patients had infections due to hemolytic Staphylococcus aureus, coagulase-positive, of which nineteen were resistant to penicillin and sixteen to tetracycline by the disc sensitivity method. The majority of the remaining 29 patients had infections due to Pneumococcus, β-Streptococcus and Enterococcus. Other organisms isolated were Proteus and H. Influenza Type D. The dosage, duration of treatment, and total